Molecular pathways: Human leukocyte antigen G(HLA-G)

Clinical Cancer Research

Volumn 19, Issue 20, 2013, Pages 5564-5571

  Curigliano, Giuseppe ^a   Criscitiello, Carmen ^a   Gelao, Lucia ^a   Goldhirsch, Aron ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HLA G ANTIGEN; HLA G ANTIGEN DERIVE PEPTIDE; PEPTIDE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER STAGING; CHORIOCARCINOMA; COLORECTAL CANCER; DIAGNOSTIC VALUE; DRUG MECHANISM; DRUG TARGETING; ENDOMETRIUM CANCER; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MELANOMA; MOLECULAR MECHANICS; MONITORING; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN STRUCTURE; REGULATORY T LYMPHOCYTE; STOMACH CANCER; UTERINE CERVIX CANCER;

HLA-G ANTIGENS; HUMANS; NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84886392614     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3697     Document Type: Article

References (60)

1. Carosella ED, Favier B, Rouas-Freiss N, Moreau P, Lemaoult J. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 2008;111:4862-70.
2. Park GM, Lee S, Park B, Kim E, Shin J, Cho K, et al. Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem Biophys Res Commun 2004;313:606-11.
3. Fons P, Chabot S, Cartwright JE, Lenfant F, L'Faqihi F, Giustiniani J, et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood 2006;108:2608-15.
4. Gao GF, Willcox BE, Wyer JR, Boulter JM, O'Callaghan CA, Maenaka K, et al. Classical and nonclassical class I major histocompatibility complex molecules exhibit subtle conformational differences that affect binding to CD8 alpha-alpha. J Biol Chem 2000; 275:15232-8.
5. Lopez-Botet M, Navarro F, Llano M. How do NK cells sense the expression of HLA-G class Ib molecules? Semin Cancer Biol 1999;9: 19-26.
6. Yan WH, Fan LA. Residues Met76 and Gln79 in HLA-G alpha1 domain involve in KIR2DL4 recognition. Cell Res 2005;15:176-82.
7. Pangault C, Le Friec G, Caulet-Maugendre S, Lena H, Amiot L, Guilloux V, et al. Lung macrophages and dendritic cells express HLA-G molecules in pulmonary diseases. Hum Immunol 2002;63:83-90.
8. Urosevic M, Willers J, Mueller B, Kempf W, Burg G, Dummer R. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 2002;99:609-17.
9. Wagner SN, Rebmann V, Willers CP, Grosse-Wilde H, Goos M. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. Lancet 2000;356:220-1.
10. LeMaoult J, Krawice-Radanne I, Dausset J, Carosella ED. HLA-G1-expressing antigen-presenting cells induce immuno-suppressive CD4? T cells. Proc Natl Acad Sci U S A 2004;101:7064-9.
11. Gooden MJ, van Hall T. Infiltrating CTLs are bothered by HLA-E on tumors. Oncoimmunology 2012;1:92-3.
12. Rouas-Freiss N, Gon?calves RM-B, Menier C, Dausset J, Carosella ED. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci U S A 1997;94:11520-5.
13. Rouas-Freiss N,Marchal RE, Kirszenbaum M, Dausset J, Carosella ED. The alpha1 domain of HLA-G1and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc Natl Acad Sci U S A 1997;94:5249-54.
14. Lemaoult J, Daouya M, Wu J, Loustau M, Horuzsko A, Carosella ED. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 2007;109:2040-8.
15. Caumartin J, Favier B, Daouya M, Guillard C, Moreau P, Carosella ED, et al. Trogocytosis-based generation of suppressive NK cells. EMBO J 2007;26:1423-33.
16. Loustau M, Wiendl H, Ferrone S, Carosella ED. HLA-G 2012 conference: the 15-year milestone update. Tissue Antigens 2013;81: 127-36
17. Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF, et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 2010;116:935-44.
18. Rossetti M, Gregori S, Roncarolo MG. Granulocyte-colony stimulating factor drives the in vitro differentiation of human dendritic cells that induce anergy in na?ve T cells. Eur J Immunol 2010;40:3097-106.
19. Fournel S, Aguerre-Girr M, Huc X, Lenfant F, Alam A, Toubert A, et al. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8? cells by interacting with CD8. J Immunol 2000;164:6100-4.
20. Rajagopalan S, Bryceson YT, Kuppusamy SP, Geraghty DE, van der Meer A, Joosten I, et al. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol 2006;4:e9.
21. van der Meer A, Lukassen HG, van Lierop MJ, Wijnands F, Mosselman S, Braat DD, et al. Membrane-bound HLA-G activates proliferation and interferon-gamma production by uterine natural killer cells. Mol Hum Reprod 2004;10:189-95.
22. van der Meer A, Lukassen HG, van Cranenbroek B, Weiss EH, Braat DD, van Lierop MJ, et al. Soluble HLA-G promotes Th1-type cytokine production by cytokine-activated uterine and peripheral natural killer cells. Mol Hum Reprod 2007;13:123-33.
23. LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED. HLA-G upregulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 2005;19:662-4.
24. Pérez-Villar JJ, Melero I, Navarro F, Carretero M, Bellón T, Llano M, et al. The CD94/NKG2-A inhibitory receptor complex is involved in natural killer cell-mediated recognition of cells expressing HLA-G1. J Immunol 1997;158:5736-43.
25. Pende D, Sivori S, Accame L, Pareti L, Falco M, Geraghty D, et al. HLAG recognition by human natural killer cells. Involvement of CD94 both as inhibitory and as activating receptor complex. Eur J Immunol 1997;27:1875-80.
26. Amiot L, Ferrone S, Grosse-Wilde H, Seliger B. Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? Cell Mol Life Sci 2011;68:417-31.
27. Deschaseaux F, Delgado D, Pistoia V, Giuliani M, Morandi F, Durrbach A. HLA-G in organ transplantation: towards clinical applications. Cell Mol Life Sci 2011;68:397-404.
28. Fainardi E, Castellazzi M, Stignani M, Morandi F, Sana G, Gonzalez R, et al. Emerging topics and new perspectives on HLA-G. Cell Mol Life Sci 2011;68:433-51.
29. Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A 1998; 95:4510-5.
30. Kalhor N, Ramirez PT, Deavers MT, Malpica A, Silva EG. Immunohistochemical studies of trophoblastic tumors. Am J Surg Pathol 2009;33:633-8.
31. Mao TL, Kurman RJ, Huang CC, Lin MC, Shih IeM. Immunohistochemistry of choriocarcinoma: an aid in differential diagnosis and in elucidating pathogenesis. Am J Surg Pathol 2007;31:1726-32.
32. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990;248:220-3.
33. Amiot L, Onno M, Drenou B, Monvoisin C, Fauchet R. HLA-G class I gene expression in normal and malignant hematopoietic cells. Hum Immunol 1998;59:524-8.
34. Polakova K, Krcova M, Kuba D, Russ G. Analysis of HLA-G expression in malignant hematopoietic cells from leukemia patients. Leuk Res 2003;27:643-8.
35. YanWH,Lin A, Chen BG, Luo WD, Dai MZ, Chen XJ, et al. Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia. J Cell Mol Med 2008;12:889-98.
36. Nuckel H, Rebmann V, Durig J, Duhrsen U, Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 2005;105:1694-8.
37. Rebmann V, Nuckel H, Duhrsen U, Grosse-Wilde H. HLA-G in Bchronic lymphocytic leukaemia: clinical relevance and functional implications. Semin Cancer Biol 2007;17:430-5.
38. Giannopoulos K, Dmoszynska A, Bojarska-Junak A, Schmitt M, Rolinski J. Expression of HLA-G in patients with B-cell chronic lymphocytic leukemia (B-CLL). Folia Histochem Cytobiol 2008;46:457-60.
39. Sebti Y, Le Friec G, Pangault C, Gros F, Drénou B, Guilloux V, et al. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol 2003;64:1093-101.
40. Sebti Y, Le Maux A, Gros F, De Guibert S, Pangault C, Rouas-Freiss N, et al. Expression of functional soluble human leucocyte antigen-Gmolecules in lymphoproliferative disorders. Br J Haematol 2007;138:202-12.
41. Diepstra A, Poppema S, Boot M, Visser L,Nolte IM, Niens M, et al. HLAG protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma. Tissue Antigens 2008;71:219-26.
42. Amiot L, Le Friec G, Sebti Y, Drénou B, Pangault C, Guilloux V, et al. HLA-G and lymphoproliferative disorders. Semin Cancer Biol 2003;13: 379-85.
43. Leleu X, Le Friec G, Facon T, Amiot L, Fauchet R, Hennache B, et al. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Cancer Res 2005;11:7297-303.
44. Menier C, Prevot S, Carosella ED, Rouas-Freiss N. Human leukocyte antigen-G is expressed in advanced-stage ovarian carcinoma of highgrade histology. Hum Immunol 2009;70:1006-9.
45. He X, Dong DD, Yie SM, Yang H, Cao M, Ye SR, et al. HLA-G expression in human breast cancer: implications for diagnosis and prognosis, and effect on allocytotoxic lymphocyte response after hormone treatment in vitro. Ann Surg Oncol 2010;17: 1459-69.
46. de Kruijf EM, Sajet A, van Nes JG, Natanov R, Putter H, Smit VT, et al. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol 2010;185:7452-9.
47. Bijen CB, Bantema-Joppe EJ, de Jong RA, Leffers N, Mourits MJ, Eggink HF, et al. The prognostic role of classical and nonclassicalMHC class I expression in endometrial cancer. Int J Cancer 2010;126: 1417-27.
48. Davidson B, Elstrand MB, McMaster MT, Berner A, Kurman RJ, Risberg B, et al. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol 2005;96:42-7.
49. Singer G, Rebmann V, Chen YC, Liu HT, Ali SZ, Reinsberg J, et al. HLAG is a potential tumor marker in malignant ascites. Clin Cancer Res 2003;9:4460-4.
50. Zheng N, Wang CX, Zhang X, Du LT, Zhang J, Kan SF, et al. Upregulation of HLA-G expression in cervical premalignant and malignant lesions. Tissue Antigens 2011;77:218-24.
51. Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM. Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol 2007;128:1002-9.
52. Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol 2007;20:375-83.
53. Du L, Xiao X, Wang C, Zhang X, Zheng N, Wang L, et al. Human leukocyte antigen-G is closely associated with tumor immune escape in gastric cancer by increasing local regulatory T cells. Cancer Sci 2011;102:1272-80.
54. Cai MY, Xu YF, Qiu SJ, Ju MJ, Gao Q, Li YW, et al. Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinomafollowing curative resection. Clin Cancer Res 2009;15:4686-93.
55. Alegre E, Howangyin KY, Favier B, Baudhuin J, Lesport E, Daouya M, et al. Membrane redistributions through multi-intercellular exchanges and serial trogocytosis. Cell Res 2010;20:1239-51.
56. Sch?utt P, Sch?utt B, Switala M, Bauer S, Stamatis G, Opalka B, et al. Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients. Hum Immunol 2010;71:489-95.
57. Komohara Y, Harada M, Ishihara Y, Suekane S, Noguchi M, Yamada A, et al. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma. Oncol Rep 2007;18: 1463-8.
58. Michelin S, Gallegos CE, Dubner D, Favier B, Carosella ED. Ionizing radiation modulates the surface expression of human leukocyte antigen-G in a human melanoma cell line. Hum Immunol 2009;70: 1010-15.
59. Moreau P, Mouillot G, Rousseau P, Marcou C, Dausset J, Carosella ED. HLA-G gene repression is reversed by demethylation. Proc Natl Acad Sci U S A 2003;100:1191-6.
60. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.